B 动脉智库 9月全球医疗健康领域按 2025 年 9 月全球医疗健康领域投融资月报 《2025年9月全球医疗健康领域投融资月报》由动脉橙发布，据动脉智库不完全统计，2025年9月全球医疗健康领域共发生175 起融资事件（不含IPO、定向增发等），披露融资总额约101.88亿美元（约727.16亿人民币），其中国内68起、总额9.56亿美 元，海外107起、总额92.32亿美元。环比8月，本月融资规模大幅上涨，事件数环比升约15.13%，融资总额环比升约 183.09%，共发生16起过亿美元事件（15起在海外、1起在国内），涉及专业药房、睡眠健康、生物制药、基因治疗等领域企 业，如Shields Health Solutions、Oura Health、Kriya Therapeutics等。细分领域中，生物医药融资事件数最多（73起，占 41.71%），数字健康融资总额最高（57.73亿美元，占56.67%），其中Shields Health Solutions获35亿美元融资居首，该公司为 全美超80个医疗系统提供专业药房服务。融资轮次上，A轮占比最高（31%），其次是B轮（18%）、未公开（17%）、种 ...

2025年9月，全球医疗健康领域迎来一场资本与创新的盛宴，单月融资总额飙升至101.88亿美元，环比暴涨183.09%，创下年内新高。这一惊人数字背 后，是175起融资事件的密集爆发，其中大额融资频现，过亿美元项目多达16起，勾勒出全球医疗健康产业新一轮的跃迁图景。更令人瞩目的是，数 字健康领域以57.73亿美元的融资额占据半壁江山，占比高达56.67%，成为当之无愧的资本焦点。 本月最引人注目的无疑是Shields Health Solutions获得的35亿美元巨额融资，一举刷新单笔融资纪录。这家为全美超80个医疗系统提供专业药房服务的 公司，正借助资本力量加速整合医疗资源。与此同时，睡眠科技明星Oura Health完成8.75亿美元E轮融资，估值逼近110亿美元，并配套2.5亿美元信贷 额度，剑指全球智能穿戴与个性化健康管理前沿。而在远程医疗领域，Strive Health凭借5.5亿美元融资，构建起融合AI与临床护理的肾脏病全周期管 理闭环，预示着专科远程护理的规模化落地已成趋势。 生物医药领域则延续高热度，73起融资事件领跑细分赛道。基因治疗公司Kriya Therapeutics斩获3.2亿美元 ...

Core Viewpoint - China National Pharmaceutical Group Corporation (China Pharmaceutical) is committed to sustainable development and integrating ESG principles into its corporate strategy and daily operations, while facing external competition and internal reform challenges [1][8]. Group 1: Financial Performance - In the first half of 2025, China Pharmaceutical achieved operating revenue of 17.076 billion yuan and a net profit attributable to shareholders of 294 million yuan [1]. Group 2: Green Manufacturing System Upgrade - China Pharmaceutical is actively promoting low-carbon transformation across its supply chain, with subsidiaries Tianfang Pharmaceutical and Sanyo Pharmaceutical recognized as national-level green factories, with Sanyo achieving "zero-carbon factory" status [2]. - Tianfang Pharmaceutical has invested in a 3.7MW distributed photovoltaic system and implemented intelligent upgrades to its fermentation tank motor systems, enhancing energy efficiency and reducing emissions [2]. Group 3: Innovation and R&D - The company emphasizes innovation as a core driver of development, with a research team of 317 members and a 3.06% increase in R&D expenses in the first half of 2025 [3]. - The company has made significant progress in product development, obtaining production approvals for five products and filing 17 invention patents [3]. Group 4: Social Responsibility - China Pharmaceutical is dedicated to expanding healthcare accessibility, particularly in remote areas, through partnerships with local governments and healthcare institutions [4]. - The company has collaborated with UNICEF to provide maternal and infant medical equipment in Uzbekistan, enhancing local healthcare capabilities [4]. Group 5: Governance Structure Optimization - The company has established a three-tier ESG governance structure to ensure comprehensive oversight and management of ESG initiatives [7]. - In the first half of 2025, China Pharmaceutical achieved ISO37301 compliance management system certification and revised several governance documents to enhance decision-making transparency and protect shareholder rights [7]. Group 6: ESG Commitment - China Pharmaceutical has received an A rating in the 2025 ESG assessment, positioning itself as an industry benchmark in green development, social responsibility, and governance innovation [8].